Cargando…
Effect of SARS CoV2-Neutralizing Monoclonal Antibody on Hospitalization and Mortality in Long-Term Care Facility Residents
To measure the association between intravenous administration of monoclonal antibody bamlanivimab (LY-CoV555) to long-term care facility (LTCF) residents recently diagnosed with pre-symptomatic, mild-to-moderate COVID-19 and are considered high risk for disease progression with mortality, hospitaliz...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
JKL International LLC
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9466966/ https://www.ncbi.nlm.nih.gov/pubmed/36186125 http://dx.doi.org/10.14336/AD.2022.0205 |
_version_ | 1784788094714642432 |
---|---|
author | Murillo, Monika Lomiguen, Christine Terrell, Mark King, Ashley Lin, James Ferretti, Silvia |
author_facet | Murillo, Monika Lomiguen, Christine Terrell, Mark King, Ashley Lin, James Ferretti, Silvia |
author_sort | Murillo, Monika |
collection | PubMed |
description | To measure the association between intravenous administration of monoclonal antibody bamlanivimab (LY-CoV555) to long-term care facility (LTCF) residents recently diagnosed with pre-symptomatic, mild-to-moderate COVID-19 and are considered high risk for disease progression with mortality, hospitalization, and adverse effects. A retrospective analysis of LTCF residents with confirmed COVID-19, pre-symptomatic, mild to moderate disease, who were treated with bamlanivimab (LY-CoV555) were compared to similar LTCF residents who did not receive monoclonal antibody treatment. Dependent variables investigated included mortality and hospitalization as primary outcomes with adverse effects as the secondary outcome. A total of 107 residents from three LTCFs were diagnosed with pre-symptomatic, mild-to-moderate COVID-19 between November 1, 2020, and December 31, 2020. Of the 107 study participants, 44 residents provided consent to treatment, of which 39 received a single intravenous infusion of neutralizing monoclonal antibody, bamlanivimab 700mg, early in the disease, and 5 received an incomplete dose. Of the 39 residents who received the full dose of bamlanivimab, 5 (12.8%) were admitted to the hospital and 4 (10.3%) died. Conversely, of the 63 residents who did not receive the monoclonal antibody, 26 (41.3 %) were admitted to the hospital and 18 (28.6%) died. Relative risk for hospitalization and death were statistically significantly lower for those residents who received the full bamlanivimab treatment. No serious adverse effects were documented on any patient. Intravenous administration of monoclonal antibody bamlanivimab (LY-CoV555) to LTCF residents recently diagnosed with pre-symptomatic, mild to moderate COVID-19 was significantly associated with reduced mortality and hospitalization. The monoclonal antibody was well-tolerated. |
format | Online Article Text |
id | pubmed-9466966 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | JKL International LLC |
record_format | MEDLINE/PubMed |
spelling | pubmed-94669662022-10-01 Effect of SARS CoV2-Neutralizing Monoclonal Antibody on Hospitalization and Mortality in Long-Term Care Facility Residents Murillo, Monika Lomiguen, Christine Terrell, Mark King, Ashley Lin, James Ferretti, Silvia Aging Dis Original Artcile To measure the association between intravenous administration of monoclonal antibody bamlanivimab (LY-CoV555) to long-term care facility (LTCF) residents recently diagnosed with pre-symptomatic, mild-to-moderate COVID-19 and are considered high risk for disease progression with mortality, hospitalization, and adverse effects. A retrospective analysis of LTCF residents with confirmed COVID-19, pre-symptomatic, mild to moderate disease, who were treated with bamlanivimab (LY-CoV555) were compared to similar LTCF residents who did not receive monoclonal antibody treatment. Dependent variables investigated included mortality and hospitalization as primary outcomes with adverse effects as the secondary outcome. A total of 107 residents from three LTCFs were diagnosed with pre-symptomatic, mild-to-moderate COVID-19 between November 1, 2020, and December 31, 2020. Of the 107 study participants, 44 residents provided consent to treatment, of which 39 received a single intravenous infusion of neutralizing monoclonal antibody, bamlanivimab 700mg, early in the disease, and 5 received an incomplete dose. Of the 39 residents who received the full dose of bamlanivimab, 5 (12.8%) were admitted to the hospital and 4 (10.3%) died. Conversely, of the 63 residents who did not receive the monoclonal antibody, 26 (41.3 %) were admitted to the hospital and 18 (28.6%) died. Relative risk for hospitalization and death were statistically significantly lower for those residents who received the full bamlanivimab treatment. No serious adverse effects were documented on any patient. Intravenous administration of monoclonal antibody bamlanivimab (LY-CoV555) to LTCF residents recently diagnosed with pre-symptomatic, mild to moderate COVID-19 was significantly associated with reduced mortality and hospitalization. The monoclonal antibody was well-tolerated. JKL International LLC 2022-10-01 /pmc/articles/PMC9466966/ /pubmed/36186125 http://dx.doi.org/10.14336/AD.2022.0205 Text en copyright: © 2022 Murillo et al. https://creativecommons.org/licenses/by/2.0/this is an open access article distributed under the terms of the creative commons attribution license, which permits unrestricted use, distribution and reproduction in any medium provided that the original work is properly attributed. |
spellingShingle | Original Artcile Murillo, Monika Lomiguen, Christine Terrell, Mark King, Ashley Lin, James Ferretti, Silvia Effect of SARS CoV2-Neutralizing Monoclonal Antibody on Hospitalization and Mortality in Long-Term Care Facility Residents |
title | Effect of SARS CoV2-Neutralizing Monoclonal Antibody on Hospitalization and Mortality in Long-Term Care Facility Residents |
title_full | Effect of SARS CoV2-Neutralizing Monoclonal Antibody on Hospitalization and Mortality in Long-Term Care Facility Residents |
title_fullStr | Effect of SARS CoV2-Neutralizing Monoclonal Antibody on Hospitalization and Mortality in Long-Term Care Facility Residents |
title_full_unstemmed | Effect of SARS CoV2-Neutralizing Monoclonal Antibody on Hospitalization and Mortality in Long-Term Care Facility Residents |
title_short | Effect of SARS CoV2-Neutralizing Monoclonal Antibody on Hospitalization and Mortality in Long-Term Care Facility Residents |
title_sort | effect of sars cov2-neutralizing monoclonal antibody on hospitalization and mortality in long-term care facility residents |
topic | Original Artcile |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9466966/ https://www.ncbi.nlm.nih.gov/pubmed/36186125 http://dx.doi.org/10.14336/AD.2022.0205 |
work_keys_str_mv | AT murillomonika effectofsarscov2neutralizingmonoclonalantibodyonhospitalizationandmortalityinlongtermcarefacilityresidents AT lomiguenchristine effectofsarscov2neutralizingmonoclonalantibodyonhospitalizationandmortalityinlongtermcarefacilityresidents AT terrellmark effectofsarscov2neutralizingmonoclonalantibodyonhospitalizationandmortalityinlongtermcarefacilityresidents AT kingashley effectofsarscov2neutralizingmonoclonalantibodyonhospitalizationandmortalityinlongtermcarefacilityresidents AT linjames effectofsarscov2neutralizingmonoclonalantibodyonhospitalizationandmortalityinlongtermcarefacilityresidents AT ferrettisilvia effectofsarscov2neutralizingmonoclonalantibodyonhospitalizationandmortalityinlongtermcarefacilityresidents |